We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 238

Other industry news: February 9 2015

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • February 9 2015

Health Canada has updated the Guidance Document: Patented Medicines (Notice of Compliance) Regulations

Finding of non-infringement upheld on appeal

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • February 9 2015

The Court of Appeal dismissed an appeal of a decision of the Court in a NOC proceeding finding that an allegation of non-infringement was justified

Court of Appeal upholds decision relating to sildenafil use patent

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 27 2014

Pfizer Ireland Pharmaceuticals v. Apotex Inc., 2014 FCA 13 Drug: VIAGRA sildenafil In Apotex' action for impeachment of the Pfizer patent

Appeal in NOC Proceeding dismissed as moot

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • February 9 2015

The Court of Appeal granted Teva’s motion to have an appeal from a NOC Proceeding dismissed as moot. The Respondent’s request for an oral hearing of

Court of Appeal strikes paragraphs relating to issue estoppel and abuse of process from statement of defence

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • March 21 2011

The Court of Appeal heard an appeal from the Motions Judge where the majority of impugned paragraphs in the Statement of Defence were allowed to stand

Appeal dismissed for mootness

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • July 4 2011

The intervener, the Canadian Generic Pharmaceutical Association (CGPA), brought a motion to dismiss the appeal by Epicept on the basis of mootness

With quantum of damages settled, parties unable to agree on quantum of costs or calculation of pre- and post-judgment interest in Section 8 case

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • August 14 2014

In the Federal Court’s earlier decision (summary here), the parties were instructed to attempt to reach an agreement on the quantity of damages and

Industry news

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • December 16 2014

The Patented Medicine Prices Review Board (PMPRB) has released a new report titled "Generic Drugs in Canada, 2013", which compares the prices of

Patent not eligible for listing: patent claiming one medicinal ingredient,but directed to a fixed-dose combination of medicines

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • October 15 2014

This was an appeal from two decisions for three proceedings before Prothonotary Milczynski, in which she determined that a patent could not be listed

Other industry news

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • October 27 2010

The Government has published amendments to the Patented Medicines (Notice of Compliance) Regulations